Idarubicin in advanced breast cancer: A phase II study

R. Lionetto, P. Pronzato, P. F. Conte, M. R. Sertoli, D. Amoroso, R. Rosso

Research output: Contribution to journalArticlepeer-review


Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.

Original languageEnglish
Pages (from-to)1439-1440
Number of pages2
JournalCancer Treatment Reports
Issue number12
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Idarubicin in advanced breast cancer: A phase II study'. Together they form a unique fingerprint.

Cite this